NIKKEI 225
38,471.20 -761.60 (-1.94%) HANG SENG
16,248.97 -351.49 (-2.12%) CRUDE OIL
85.14 -0.27 (-0.32%) GOLD FUTURES
2,404.10 +21.10 (+0.89%) DOW
37,829.19 +94.08 (+0.25%) Bitcoin GBP
50,576.88 -609.11 (-1.19%)
Ardelyx, Inc. (ARDX)
- GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
WALTHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on March 25, 2024, the compensation committee of the company’s board of directors granted a non-qualified stock option award to purchase 205,000 shares of its common stock and a restricted stock unit award for 160,000 shares in
- GlobeNewswire
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Mike Kelliher to the position of Executive Vice President, Corporate Development and Strategy. Mr. Kelliher, an accomplished leader with more than 20 years of experience in the biopharmaceutical industry, brings to
- Simply Wall St.
Institutional investors may overlook Ardelyx, Inc.'s (NASDAQ:ARDX) recent US$195m market cap drop as long-term gains remain positive
Key Insights Given the large stake in the stock by institutions, Ardelyx's stock price might be vulnerable to their...
